1505 O'Brien Drive
Tel: 1 (650) 271-9888
4 articles with Synthekine
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Synthekine Presents Data at American Society of Hematology Annual Meeting Showing Orthogonal IL-2 Ligand Drives Deeper and More Durable Response of CD-19 CAR-T
Synthekine Inc., an engineered cytokine therapeutics company, today announced in vivo data presented at the American Society of Hematology Annual Meeting showing STK-009, its orthogonal IL-2 ligand, improved the efficacy and durability of SYNCAR-001, its CD-19 targeted CAR-T cell therapy modified with an orthogonal IL-2 receptor
Engineered cytokine therapeutics company Synthekine announced on Thursday that it has concluded an $82 million Series A funding round.
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
Series A led by Canaan Partners, Samsara BioCapital and The Column Group Foundational research into cytokine structural biology and immune function licensed from Stanford University Nils Lonberg joins founding investors on board of directors